JP2007505148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505148A5 JP2007505148A5 JP2006526388A JP2006526388A JP2007505148A5 JP 2007505148 A5 JP2007505148 A5 JP 2007505148A5 JP 2006526388 A JP2006526388 A JP 2006526388A JP 2006526388 A JP2006526388 A JP 2006526388A JP 2007505148 A5 JP2007505148 A5 JP 2007505148A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- alkyl
- disease
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- FUZYTVDVLBBXDL-UHFFFAOYSA-N 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide Chemical compound N1C2=CC=C(Cl)C=C2C2=C1C(C(=O)N)CCC2 FUZYTVDVLBBXDL-UHFFFAOYSA-N 0.000 claims 3
- -1 cyano, nitro, amino Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 235000001508 sulfur Nutrition 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000011759 adipose tissue development Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004694 alkoxyaminocarbonyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50281103P | 2003-09-12 | 2003-09-12 | |
| US60/502,811 | 2003-09-12 | ||
| US53144303P | 2003-12-19 | 2003-12-19 | |
| US60/531,443 | 2003-12-19 | ||
| US56050904P | 2004-04-07 | 2004-04-07 | |
| US60/560,509 | 2004-04-07 | ||
| PCT/US2004/029942 WO2005026112A2 (en) | 2003-09-12 | 2004-09-13 | Methods of treating a disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505148A JP2007505148A (ja) | 2007-03-08 |
| JP2007505148A5 true JP2007505148A5 (enExample) | 2007-11-08 |
| JP4908215B2 JP4908215B2 (ja) | 2012-04-04 |
Family
ID=34317479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526388A Expired - Lifetime JP4908215B2 (ja) | 2003-09-12 | 2004-09-13 | 疾患の治療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050209300A1 (enExample) |
| EP (1) | EP1677794B1 (enExample) |
| JP (1) | JP4908215B2 (enExample) |
| CA (1) | CA2538759C (enExample) |
| ES (1) | ES2530972T3 (enExample) |
| WO (1) | WO2005026112A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050096256A1 (en) | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20070105109A1 (en) * | 2003-07-02 | 2007-05-10 | Geesaman Bard J | Sirt1 and genetic disorders |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| TW200526668A (en) * | 2003-10-02 | 2005-08-16 | Salmedix Inc | Substituted indole derivatives |
| EP1694323A4 (en) * | 2003-12-19 | 2009-05-13 | Elixir Pharmaceuticals Inc | METHOD FOR TREATING A DISEASE |
| EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| EP1817025A2 (en) | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20090022694A1 (en) * | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| WO2008019825A1 (en) * | 2006-08-14 | 2008-02-21 | Santhera Pharmaceuticals (Schweiz) Ag | Use of tricyclic indole derivatives for the treatment of muscular diseases |
| EP1891949A1 (en) * | 2006-08-14 | 2008-02-27 | Santhera Pharmaceuticals (Schweiz) AG | Use of tricyclic indole derivatives for the treatment of muscular atrophy |
| US20110009474A1 (en) * | 2007-04-12 | 2011-01-13 | President And Fellows Of Harvard College | Sirtuin based methods and compositions for treating beta-catenin-related conditions |
| WO2009099643A1 (en) * | 2008-02-07 | 2009-08-13 | The J. David Gladstone Institutes | Use of sirt1 activators or inhibitors to modulate an immune response |
| EP2367563A4 (en) | 2008-12-08 | 2012-12-19 | Univ Northwestern | PROCESS FOR HSF-1 MODULATION |
| WO2012142256A2 (en) * | 2011-04-12 | 2012-10-18 | The Regents Of The University Of California | Modulators of mitochondrial protein import |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| AU2015315174B2 (en) * | 2014-09-10 | 2019-12-12 | Epizyme, Inc. | Smyd inhibitors |
| CA2968884A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
| PY2438443A (es) | 2023-05-16 | 2025-06-18 | Aop Orphan Ip Ag | Nuevos polimorfos de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma cristalina |
| PY2438446A (es) | 2023-05-16 | 2025-06-18 | Aop Orphan Ip Ag | Preparación de (s)-6-cloro-2,3,4,9- tetrahidro-1h-carbazol-1-carboxamida en forma enantioméricamente enriquecida mediante proceso de resolución |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769298A (en) * | 1971-04-02 | 1973-10-30 | Pfizer | Substituted aminomethylcarbazoles |
| BE793493A (fr) * | 1971-12-30 | 1973-06-29 | Hoffmann La Roche | Composes tricycliques |
| DE2226703A1 (de) * | 1972-05-25 | 1973-12-13 | Schering Ag | Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung |
| US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| DE2431292A1 (de) * | 1974-06-27 | 1976-01-15 | Schering Ag | Neue carbazol-derivate |
| BG25793A3 (bg) * | 1973-07-18 | 1978-12-12 | Schering Aktiengesellschaft | Метод за получаване на карбазолови деривати |
| MX9700696A (es) * | 1994-07-27 | 1997-04-30 | Sankyo Co | Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos. |
| US6045398A (en) * | 1995-07-10 | 2000-04-04 | International Business Machines Corporation | Battery accepting unit and battery pack |
| US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
| WO2002102981A2 (en) * | 2001-06-15 | 2002-12-27 | The Trustees Of Columbia University In The City Of New York | SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS |
| JP2005518375A (ja) * | 2001-12-14 | 2005-06-23 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇタンパク質結合受容体（ｇｐｃｒ）のためのリガンドとしてのテトラヒドロカルバゾール誘導体 |
| CA2473740A1 (en) * | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
-
2004
- 2004-09-13 WO PCT/US2004/029942 patent/WO2005026112A2/en not_active Ceased
- 2004-09-13 CA CA2538759A patent/CA2538759C/en not_active Expired - Lifetime
- 2004-09-13 US US10/940,269 patent/US20050209300A1/en not_active Abandoned
- 2004-09-13 JP JP2006526388A patent/JP4908215B2/ja not_active Expired - Lifetime
- 2004-09-13 EP EP04788727.8A patent/EP1677794B1/en not_active Expired - Lifetime
- 2004-09-13 ES ES04788727T patent/ES2530972T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513370A5 (enExample) | ||
| JP2007515429A5 (enExample) | ||
| RU2309956C2 (ru) | Производные индол-3-карбоксамида в качестве активаторов глюкокиназы | |
| IL183876A0 (en) | Aminocarboxylic acid derivative and medicinal use thereof | |
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| JP2009530399A5 (enExample) | ||
| RU2010154279A (ru) | Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов | |
| CY1121639T1 (el) | Συνθεσεις που περιλαμβανουν προφαρμακα νουκλεοτιδιων και ολιγονουκλεοτιδιων | |
| JP2002520316A5 (enExample) | ||
| MY156747A (en) | Isoxazolo-pyridine derivatives | |
| JP2009529541A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2004504388A5 (enExample) | ||
| JP2005097323A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2019518764A5 (enExample) | ||
| CA2634381A1 (en) | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | |
| JP2006507220A5 (enExample) | ||
| RU2010143817A (ru) | Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета | |
| FR2854633A1 (fr) | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique | |
| JP2007532627A5 (enExample) | ||
| JP2018530582A5 (enExample) | ||
| CA2533747A1 (en) | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors | |
| JP2010522710A5 (enExample) | ||
| JP2013537240A5 (enExample) |